Skip to content

Elite Pharmaceuticals, Inc.: 10-Q filed 2025-11-14

What Elite Pharmaceuticals, Inc. reported in its quarterly report filed 2025-11-14 (fiscal Q2 2026): 48 published measures, 134 facts as tagged in accession 0001493152-25-023477.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-14
Fiscal period
fiscal Q2 2026
Accession
0001493152-25-023477 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Elite Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-30117,247,811USD
At 2025-03-3196,387,477USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3055,662,843USD
At 2025-03-3142,872,448USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-3061,584,968USD
At 2025-06-3047,682,643USD
At 2025-03-3153,515,029USD
At 2024-09-3047,267,020USD
At 2024-06-3058,250,920USD
At 2024-03-3157,582,818USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-3013,702,407USD92
2025-04-01 to 2025-09-307,817,692USD183
2025-04-01 to 2025-06-30-5,884,715USD91
2024-07-01 to 2024-09-30-11,036,229USD92
2024-04-01 to 2024-09-30-10,420,456USD183
2024-04-01 to 2024-06-30615,773USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-04-01 to 2025-09-3019,880,115USD183
2024-04-01 to 2024-09-304,601,307USD183

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-04-01 to 2025-09-30321,538USD183
2024-04-01 to 2024-09-30870,972USD183

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-3036,321,704USD92
2025-04-01 to 2025-09-3076,532,801USD183
2024-07-01 to 2024-09-3018,880,345USD92
2024-04-01 to 2024-09-3037,683,408USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-04-01 to 2025-09-30-4,247,152USD183
2024-04-01 to 2024-09-30-495,592USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-04-01 to 2025-09-30-321,538USD183
2024-04-01 to 2024-09-30-1,645,722USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-112,886,234USD
At 2025-03-31-120,703,926USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,071,897,174shares92
2025-04-01 to 2025-09-301,070,180,140shares183
2024-07-01 to 2024-09-301,068,273,108shares92
2024-04-01 to 2024-09-301,068,273,108shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,141,536,381shares92
2025-04-01 to 2025-09-301,081,817,730shares183
2024-07-01 to 2024-09-301,068,273,108shares92
2024-04-01 to 2024-09-301,068,273,108shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-300.01USD/shares92
2025-04-01 to 2025-09-300.01USD/shares183
2024-07-01 to 2024-09-30-0.01USD/shares92
2024-04-01 to 2024-09-30-0.01USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-300.01USD/shares92
2025-04-01 to 2025-09-300.01USD/shares183
2024-07-01 to 2024-09-30-0.01USD/shares92
2024-04-01 to 2024-09-30-0.01USD/shares183

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,987,940USD92
2025-04-01 to 2025-09-307,308,441USD183
2024-07-01 to 2024-09-301,517,203USD92
2024-04-01 to 2024-09-301,749,182USD183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-3010,097,979USD
At 2025-03-3110,327,245USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-308,213,746USD92
2025-04-01 to 2025-09-3029,913,453USD183
2024-07-01 to 2024-09-303,484,943USD92
2024-04-01 to 2024-09-307,348,999USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3085,793,698USD
At 2025-03-3157,739,147USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3010,673,516USD
At 2025-03-3111,840,435USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-303,424,625USD
At 2025-03-312,957,584USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-09-305,637,802USD
At 2025-03-315,637,802USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-3040,871,924USD
At 2025-03-3129,207,028USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,859,287USD92
2025-04-01 to 2025-09-3011,385,550USD183
2024-07-01 to 2024-09-304,712,485USD92
2024-04-01 to 2024-09-309,323,207USD183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-3018,164,934USD
At 2025-03-3116,240,376USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-3014,073,033USD92
2025-04-01 to 2025-09-3041,299,003USD183
2024-07-01 to 2024-09-308,197,428USD92
2024-04-01 to 2024-09-3016,672,206USD183

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-07-01 to 2025-09-3022,248,671USD92
2025-04-01 to 2025-09-3035,233,798USD183
2024-07-01 to 2024-09-3010,682,917USD92
2024-04-01 to 2024-09-3021,011,202USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,385,306USD92
2025-04-01 to 2025-09-303,060,270USD183
2024-07-01 to 2024-09-301,966,094USD92
2024-04-01 to 2024-09-304,129,621USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-301,073,363,108shares
At 2025-03-311,068,363,108shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3027,080,586USD
At 2024-09-309,999,087USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-30173,704,576USD
At 2025-03-31173,457,329USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-301,770,693USD
At 2025-03-312,000,284USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-301,796,473USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-09-3027,677,483USD
At 2025-03-3127,355,945USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-09-3017,579,504USD
At 2025-03-3117,028,700USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-306,152,304USD
At 2025-03-313,795,227USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30139,494USD
At 2025-03-31976,358USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2025-03-315,556USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-3015,690,347USD92
2025-04-01 to 2025-09-3015,126,133USD183
2024-07-01 to 2024-09-30-9,519,026USD92
2024-04-01 to 2024-09-30-8,671,274USD183

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-3013,702,407USD92
2025-04-01 to 2025-09-307,817,692USD183
2024-07-01 to 2024-09-30-11,036,229USD92
2024-04-01 to 2024-09-30-10,420,456USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-304,029,199USD92
2025-04-01 to 2025-09-307,433,283USD183
2024-07-01 to 2024-09-302,273,744USD92
2024-04-01 to 2024-09-304,242,898USD183

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-07-01 to 2025-09-30275,391USD92
2025-04-01 to 2025-09-30550,804USD183
2024-07-01 to 2024-09-30227,356USD92
2024-04-01 to 2024-09-30622,947USD183

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-307,476,601USD92
2025-04-01 to 2025-09-30-14,787,320USD183
2024-07-01 to 2024-09-30-13,003,969USD92
2024-04-01 to 2024-09-30-16,020,273USD183

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2025-04-01 to 2025-09-306,561,582USD183
2024-04-01 to 2024-09-301,317,391USD183

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-04-01 to 2025-09-30128,920USD183
2024-04-01 to 2024-09-30367,135USD183

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-04-01 to 2025-09-30796,101USD183
2024-04-01 to 2024-09-30496,262USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-09-3012,414,971USD183
2024-04-01 to 2024-09-302,014,838USD183

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-09-301,924,558USD183
2024-04-01 to 2024-09-301,234,481USD183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-09-30467,041USD183
2024-04-01 to 2024-09-30-731,026USD183

Inspect the source

Entity
Elite Pharmaceuticals, Inc. / CIK 0001053369
Captured
2026-09-20T05:17:33.154Z
SEC response SHA-256
b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053369.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))